EMEA accepts AMR101 MAA

Amarin Corp. plc (NASDAQ:AMRN) gained $0.55 (84%) to $1.20 on Wednesday after announcing that EMEA accepted for review an MAA for AMR101 to treat Huntington's disease. The 97% pure ethyl-eicosapentaen...